CANOPY GROWTH CORP (WEED.CA) Stock Fundamental Analysis
TSX:WEED - Toronto Stock Exchange - CA1380357048 - Common Stock - Currency: CAD
Overall WEED gets a fundamental rating of 3 out of 10. We evaluated WEED against 34 industry peers in the Pharmaceuticals industry. While WEED seems to be doing ok healthwise, there are quite some concerns on its profitability. WEED is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
WEED had negative earnings in the past year.
In the past year WEED has reported a negative cash flow from operations.
WEED had negative earnings in each of the past 5 years.
In the past 5 years WEED always reported negative operating cash flow.
1.2 Ratios
WEED has a worse Return On Assets (-40.34%) than 70.59% of its industry peers.
The Return On Equity of WEED (-79.41%) is worse than 61.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.34% | ||
| ROE | -79.41% | ||
| ROIC | N/A |
ROA(3y)-63.49%
ROA(5y)-47.06%
ROE(3y)-181.56%
ROE(5y)-123.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of WEED (30.40%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of WEED has grown nicely.
WEED does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.93%
GM growth 5Y16.63%
2. Health
2.1 Basic Checks
WEED does not have a ROIC to compare to the WACC, probably because it is not profitable.
WEED has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, WEED has less shares outstanding
WEED has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -9.77, we must say that WEED is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of WEED (-9.77) is worse than 82.35% of its industry peers.
A Debt/Equity ratio of 0.79 indicates that WEED is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.79, WEED is doing worse than 70.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.77 |
ROIC/WACCN/A
WACC9.25%
2.3 Liquidity
A Current Ratio of 3.52 indicates that WEED has no problem at all paying its short term obligations.
The Current ratio of WEED (3.52) is better than 88.24% of its industry peers.
WEED has a Quick Ratio of 2.58. This indicates that WEED is financially healthy and has no problem in meeting its short term obligations.
WEED has a better Quick ratio (2.58) than 85.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.52 | ||
| Quick Ratio | 2.58 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 74.44% over the past year.
WEED shows a decrease in Revenue. In the last year, the revenue decreased by -7.16%.
WEED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.60% yearly.
EPS 1Y (TTM)74.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.63%
Revenue 1Y (TTM)-7.16%
Revenue growth 3Y-18.39%
Revenue growth 5Y5.6%
Sales Q2Q%-4.77%
3.2 Future
The Earnings Per Share is expected to grow by 14.03% on average over the next years. This is quite good.
Based on estimates for the next years, WEED will show a small growth in Revenue. The Revenue will grow by 1.96% on average per year.
EPS Next Y51.93%
EPS Next 2Y38.97%
EPS Next 3Y24.86%
EPS Next 5Y14.03%
Revenue Next Year-16.49%
Revenue Next 2Y-5.42%
Revenue Next 3Y-1.49%
Revenue Next 5Y1.96%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
WEED reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year WEED is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
WEED's earnings are expected to grow with 24.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.97%
EPS Next 3Y24.86%
5. Dividend
5.1 Amount
No dividends for WEED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:WEED (4/25/2025, 7:00:00 PM)
1.94
-0.13 (-6.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners6.95%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap407.65M
Analysts47.5
Price Target3.81 (96.39%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-166.14%
Min EPS beat(2)-231.12%
Max EPS beat(2)-101.15%
EPS beat(4)0
Avg EPS beat(4)-174.49%
Min EPS beat(4)-240.27%
Max EPS beat(4)-101.15%
EPS beat(8)1
Avg EPS beat(8)-220.62%
EPS beat(12)1
Avg EPS beat(12)-210.52%
EPS beat(16)4
Avg EPS beat(16)-164.13%
Revenue beat(2)1
Avg Revenue beat(2)2.88%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)6.06%
Revenue beat(4)2
Avg Revenue beat(4)2.6%
Min Revenue beat(4)-8.11%
Max Revenue beat(4)12.74%
Revenue beat(8)4
Avg Revenue beat(8)2.36%
Revenue beat(12)5
Avg Revenue beat(12)-2.05%
Revenue beat(16)6
Avg Revenue beat(16)-2.85%
PT rev (1m)-2.5%
PT rev (3m)-38.28%
EPS NQ rev (1m)-20.51%
EPS NQ rev (3m)6.34%
EPS NY rev (1m)0.08%
EPS NY rev (3m)-21.35%
Revenue NQ rev (1m)7.13%
Revenue NQ rev (3m)-1.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.47 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.69 | ||
| P/tB | 0.89 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.22
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS1.32
BVpS2.81
TBVpS2.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.34% | ||
| ROE | -79.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.4% | ||
| FCFM | N/A |
ROA(3y)-63.49%
ROA(5y)-47.06%
ROE(3y)-181.56%
ROE(5y)-123.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.93%
GM growth 5Y16.63%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 19.12% | ||
| Cap/Sales | 2.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.52 | ||
| Quick Ratio | 2.58 | ||
| Altman-Z | -9.77 |
F-Score6
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)20.68%
Cap/Depr(5y)155.29%
Cap/Sales(3y)4.46%
Cap/Sales(5y)45.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.63%
EPS Next Y51.93%
EPS Next 2Y38.97%
EPS Next 3Y24.86%
EPS Next 5Y14.03%
Revenue 1Y (TTM)-7.16%
Revenue growth 3Y-18.39%
Revenue growth 5Y5.6%
Sales Q2Q%-4.77%
Revenue Next Year-16.49%
Revenue Next 2Y-5.42%
Revenue Next 3Y-1.49%
Revenue Next 5Y1.96%
EBIT growth 1Y64.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year92.97%
EBIT Next 3Y26.49%
EBIT Next 5Y16.65%
FCF growth 1Y70.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.6%
OCF growth 3YN/A
OCF growth 5YN/A